Osborne Partners Capital Management LLC Boosts Stake in Danaher Corporation $DHR

Osborne Partners Capital Management LLC raised its position in shares of Danaher Corporation (NYSE:DHR) by 2.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 98,234 shares of the conglomerate’s stock after buying an additional 2,681 shares during the quarter. Danaher comprises 1.0% of Osborne Partners Capital Management LLC’s portfolio, making the stock its 27th biggest holding. Osborne Partners Capital Management LLC’s holdings in Danaher were worth $19,476,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of DHR. Ceredex Value Advisors LLC grew its holdings in Danaher by 1.6% during the 2nd quarter. Ceredex Value Advisors LLC now owns 249,377 shares of the conglomerate’s stock worth $49,262,000 after acquiring an additional 3,862 shares in the last quarter. Chicago Capital LLC lifted its position in shares of Danaher by 11.6% in the 2nd quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate’s stock worth $2,634,000 after purchasing an additional 1,391 shares during the period. Weitz Investment Management Inc. lifted its holdings in Danaher by 6.1% during the second quarter. Weitz Investment Management Inc. now owns 526,950 shares of the conglomerate’s stock worth $104,094,000 after buying an additional 30,300 shares during the period. Nvwm LLC boosted its position in Danaher by 20.4% during the 2nd quarter. Nvwm LLC now owns 7,093 shares of the conglomerate’s stock valued at $1,401,000 after acquiring an additional 1,204 shares in the last quarter. Finally, ASR Vermogensbeheer N.V. increased its holdings in shares of Danaher by 1.9% in the 2nd quarter. ASR Vermogensbeheer N.V. now owns 322,924 shares of the conglomerate’s stock valued at $63,787,000 after acquiring an additional 6,136 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Danaher

In other news, SVP Brian W. Ellis sold 21,776 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the sale, the senior vice president directly owned 14,553 shares of the company’s stock, valued at $3,190,454.19. This represents a 59.94% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Teri List sold 3,298 shares of the firm’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total transaction of $746,997.00. Following the transaction, the director directly owned 20,762 shares of the company’s stock, valued at approximately $4,702,593. This trade represents a 13.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 30,248 shares of company stock worth $6,609,663. Company insiders own 11.20% of the company’s stock.

Wall Street Analyst Weigh In

DHR has been the topic of a number of recent research reports. JPMorgan Chase & Co. raised their price objective on Danaher from $260.00 to $270.00 and gave the company an “overweight” rating in a research report on Wednesday, October 22nd. Weiss Ratings reiterated a “hold (c)” rating on shares of Danaher in a research note on Monday, December 29th. Evercore ISI reaffirmed an “outperform” rating and issued a $250.00 price target on shares of Danaher in a report on Monday, January 5th. TD Cowen increased their price objective on Danaher from $260.00 to $270.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Finally, Morgan Stanley started coverage on Danaher in a research report on Monday, December 1st. They set an “overweight” rating and a $270.00 target price on the stock. Twenty-one equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $251.87.

Danaher Stock Performance

Shares of DHR stock opened at $234.11 on Wednesday. The business has a fifty day moving average of $229.17 and a 200 day moving average of $212.44. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $258.23. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. The firm has a market capitalization of $165.36 billion, a price-to-earnings ratio of 48.27, a price-to-earnings-growth ratio of 4.20 and a beta of 0.89.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The business had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. During the same period in the prior year, the company earned $1.71 earnings per share. The company’s revenue was up 4.4% on a year-over-year basis. As a group, research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Friday, December 26th will be given a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, December 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.5%. Danaher’s dividend payout ratio (DPR) is currently 26.39%.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.